EDA2R and small cell lung carcinoma: In contrast with the other selected molecules, high expression of EDA2R was closely related to poor prognosis [44], suggesting that it could represent a bottleneck for immunotherapy for SCLC; future research should assess whether treatments targeting EDA2R can significantly enhance the efficacy of such immunotherapy.